Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zymeworks Inc.ZYME · Entity 4458 | EVP & Chief Medical Officer | January 12, 2026 | January 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,708 |
Ending reported balance
After 2026-01-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-12 · Exercise / conversion · Acquired 17,666 · Balance 36,018 F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Row 2 · 2026-01-12 · Sale · Disposed 9,310 · Balance 26,708 F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 35,334 |
Reported balance
After 2026-01-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-12 · Exercise / conversion · Disposed 17,666 · Balance 35,334 F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025.
F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F5: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALDER BIOPHARMACEUTICALS INC
Report date October 22, 2019 · Filed October 24, 2019
Section 16 reporting ended · disclosed 2019-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-10-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-10-22 · Grant · Acquired 16,230 · Balance 21,502 F1: On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 25,518 shares of Issuer's Common Stock (the "RSU"), of which 9,288 shares had vested and the remaining 16,230 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 2). Row 2 · 2019-10-22 · Disposition to issuer · Disposed 21,502 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F3: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.47 · Expires 2022-06-12 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-22 · Disposition to issuer · Disposed 17,271 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F4: The shares subject to this stock option are fully vested. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.47 · Expires 2022-12-11 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-22 · Disposition to issuer · Disposed 31,818 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F4: The shares subject to this stock option are fully vested. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2024-02-10 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-10-22 · Disposition to issuer · Disposed 13,636 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F6: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2014 (the "2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2024-05-06 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-10-22 · Disposition to issuer · Disposed 13,636 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F7: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of May 7, 2014 (the "May 2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the May 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the May 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.90 · Expires 2024-07-07 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-10-22 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F8: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of July 8, 2014 (the "July 2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the July 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the July 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.23 · Expires 2025-01-25 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-10-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F9: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2015 (the "2015 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2015 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2015 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. F10: The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2026-01-28 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-10-22 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F10: The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor. F11: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2016 (the "2016 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2016 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2016 Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.40 · Expires 2027-01-26 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-10-22 · Disposition to issuer · Disposed 85,000 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F10: The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor. F12: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2017 Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.70 · Expires 2027-12-13 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-10-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F13: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the "December 2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the December 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the December 2017 Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.55 · Expires 2028-02-15 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-10-22 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F14: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "2018 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2029-02-05 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-10-22 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F15: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 25,518 shares of Issuer's Common Stock (the "RSU"), of which 9,288 shares had vested and the remaining 16,230 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 2).
F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.
F3: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.
F4: The shares subject to this stock option are fully vested.
F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.
F6: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2014 (the "2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
F7: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of May 7, 2014 (the "May 2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the May 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the May 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
F8: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of July 8, 2014 (the "July 2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the July 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the July 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
F9: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2015 (the "2015 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2015 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2015 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
F10: The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor.
F11: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2016 (the "2016 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2016 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2016 Vesting Commencement Date.
F12: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2017 Vesting Commencement Date.
F13: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the "December 2017 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the December 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the December 2017 Vesting Commencement Date.
F14: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "2018 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date.
F15: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2018 Filed Aug 2, 2018 17:48 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 5,040 | $0.99 | $4,989.60 |
DisclosureSEC source: 0001209191-18-045042 · doc4.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 17:28 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,040 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-18-041240 · doc4.xml · derivative · entry 5 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,204 Underlying: Common Stock · 5,040 shares Expires 2019-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 17:28 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,121 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-18-041240 · doc4.xml · derivative · entry 4 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,121 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 17:28 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 12,161 | $15.49 | $188,364.16 |
DisclosureSEC source: 0001209191-18-041240 · doc4.xml · nonDerivative · entry 3 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.225 to $15.775, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 17:28 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 5,040 | $0.99 | $4,989.60 |
DisclosureSEC source: 0001209191-18-041240 · doc4.xml · nonDerivative · entry 2 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 17:28 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 7,121 | $1.65 | $11,749.65 |
DisclosureSEC source: 0001209191-18-041240 · doc4.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:41 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,040 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-18-035868 · doc4.xml · derivative · entry 6 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,244 Underlying: Common Stock · 5,040 shares Expires 2019-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:41 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,121 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-18-035868 · doc4.xml · derivative · entry 5 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,121 Underlying: Common Stock · 7,121 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:41 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 1,100 | $18.29 | $20,115.04 |
DisclosureSEC source: 0001209191-18-035868 · doc4.xml · nonDerivative · entry 4 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.25 to $18.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:41 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 11,061 | $17.81 | $197,011.90 |
DisclosureSEC source: 0001209191-18-035868 · doc4.xml · nonDerivative · entry 3 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,931 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $18.2250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:41 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 5,040 | $0.99 | $4,989.60 |
DisclosureSEC source: 0001209191-18-035868 · doc4.xml · nonDerivative · entry 2 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:41 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 7,121 | $1.65 | $11,749.65 |
DisclosureSEC source: 0001209191-18-035868 · doc4.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. Read SEC document |
| May 16, 2018 Filed May 18, 2018 17:57 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,121 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-18-031528 · doc4.xml · derivative · entry 5 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,242 Underlying: Common Stock · 7,121 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| May 16, 2018 Filed May 18, 2018 17:57 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,040 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-18-031528 · doc4.xml · derivative · entry 4 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,284 Underlying: Common Stock · 5,040 shares Expires 2019-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| May 16, 2018 Filed May 18, 2018 17:57 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 12,161 | $15.03 | $182,757.94 |
DisclosureSEC source: 0001209191-18-031528 · doc4.xml · nonDerivative · entry 3 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.85 to $15.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| May 16, 2018 Filed May 18, 2018 17:57 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 7,121 | $1.65 | $11,749.65 |
DisclosureSEC source: 0001209191-18-031528 · doc4.xml · nonDerivative · entry 2 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. Read SEC document |
| May 16, 2018 Filed May 18, 2018 17:57 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 5,040 | $0.99 | $4,989.60 |
DisclosureSEC source: 0001209191-18-031528 · doc4.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 17:36 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001209191-18-012041 · doc4.xml · derivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Managing Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 18:30 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantThe shares subject to this option shall vest and become exer · Derivative | 50,000 | $0.00 Strike: $10.70 | $0.00 |
DisclosureSEC source: 0001209191-17-066207 · doc4.xml · derivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 18:12 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 585 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-17-041449 · doc4.xml · derivative · entry 3 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,324 Underlying: Common Stock · 585 shares Expires 2019-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 18:12 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 585 | $20.00 | $11,700.00 |
DisclosureSEC source: 0001209191-17-041449 · doc4.xml · nonDerivative · entry 2 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2017. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 18:12 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 585 | $0.99 | $579.15 |
DisclosureSEC source: 0001209191-17-041449 · doc4.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2017. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 17:25 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001209191-17-006430 · doc4.xml · derivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 18:47 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-16-153491 · doc4.xml · derivative · entry 4 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,363 Underlying: Common Stock · 3,000 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 18:47 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 500 | $23.62 | $11,810.00 |
DisclosureSEC source: 0001209191-16-153491 · doc4.xml · nonDerivative · entry 3 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.20 to $23.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4 Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 18:47 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 2,500 | $22.61 | $56,518.00 |
DisclosureSEC source: 0001209191-16-153491 · doc4.xml · nonDerivative · entry 2 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,331 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.20 to $23.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4 Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 18:47 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 3,000 | $1.65 | $4,950.00 |
DisclosureSEC source: 0001209191-16-153491 · doc4.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F2 · balance_after: Includes 831 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2016. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 18:39 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-16-148271 · doc4.xml · derivative · entry 4 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,363 Underlying: Common Stock · 3,000 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 18:39 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 400 | $24.88 | $9,950.00 |
DisclosureSEC source: 0001209191-16-148271 · doc4.xml · nonDerivative · entry 3 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.80 to $24.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4. Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 18:39 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 2,600 | $24.26 | $63,081.98 |
DisclosureSEC source: 0001209191-16-148271 · doc4.xml · nonDerivative · entry 2 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $24.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4 Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 18:39 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 3,000 | $1.65 | $4,950.00 |
DisclosureSEC source: 0001209191-16-148271 · doc4.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 19:02 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-16-145140 · doc4.xml · derivative · entry 4 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,363 Underlying: Common Stock · 3,000 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to this stock option are fully vested. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 19:02 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 702 | $31.62 | $22,198.50 |
DisclosureSEC source: 0001209191-16-145140 · doc4.xml · nonDerivative · entry 3 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.43 to $32.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 19:02 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 2,298 | $30.99 | $71,216.40 |
DisclosureSEC source: 0001209191-16-145140 · doc4.xml · nonDerivative · entry 2 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.42 to $31.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 19:02 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 3,000 | $1.65 | $4,950.00 |
DisclosureSEC source: 0001209191-16-145140 · doc4.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 18:34 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-16-140247 · doc4.xml · derivative · entry 4 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,363 Underlying: Common Stock · 3,000 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 18:34 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 100 | $33.10 | $3,310.00 |
DisclosureSEC source: 0001209191-16-140247 · doc4.xml · nonDerivative · entry 3 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 18:34 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | SaleCommon Stock | 2,900 | $32.47 | $94,173.15 |
DisclosureSEC source: 0001209191-16-140247 · doc4.xml · nonDerivative · entry 2 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $33.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 18:34 UTC | ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258 | Exercise / conversionCommon Stock | 3,000 | $1.65 | $4,950.00 |
DisclosureSEC source: 0001209191-16-140247 · doc4.xml · nonDerivative · entry 1 Smith Jeffrey T L · CIK 0001604800 · Sr. VP Translational Medicine 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.